Interventional Oncology
Interventional Oncology (INTO) is a Research & Development enterprise group that integrates the expertise of both Johnson & Johnson sectors, aiming to develop intratumoral treatments—a promising growth area within interventional oncology. We use a multidisciplinary approach to help accelerate the company’s bold vision to eliminate cancer by developing the portfolio and procedures to deliver drugs directly into tumors.
Johnson & Johnson is highly differentiated by its two sectors: MedTech and Innovative Medicine. By integrating the expertise of both sectors, we believe we are uniquely positioned to develop intratumoral therapies, technology, and procedures for lung cancer—where there is the greatest unmet need—as well as for head and neck and potentially other solid tumors.
Johnson & Johnson is highly differentiated by its two sectors: MedTech and Innovative Medicine. By integrating the expertise of both sectors, we believe we are uniquely positioned to develop intratumoral therapies, technology, and procedures for lung cancer—where there is the greatest unmet need—as well as for head and neck and potentially other solid tumors.
Why intratumoral therapy?
Intratumoral therapy has several benefits that can help address clinical unmet needs along the patient journey with the goal of:
Minimizing toxicity
Make possible a better risk-benefit proposition especially for treatment of early cancer
Increasing efficacy
Provide higher concentrations of local therapy to kill the tumor and activate anti-tumor immunity
Unlocking new therapies
Enable the use of immunotherapies, which cannot be delivered systemically
Partner with us
The INTO External Innovation team is seeking external innovations to further our intratumoral portfolio in the following areas.
Innovative intratumoral therapies
New approaches may incorporate cytotoxic agents (ideally immunogenic cell death inducers), immunostimulatory energy or agents, radio-enhancers/sensitizers and cell therapies. We seek to expand the use of controlled release and localized depot drug delivery technologies, including small molecule, protein, and RNA delivery approaches.
Integrated delivery procedure solutions
Developing, expanding and fine-tuning new technologies will empower our INTO team and its partners to plan, deliver, monitor and confirm success of intratumoral therapy delivery.
We are seeking external innovations to further our intratumoral portfolio. Contact us for partnership opportunities.
Who we are
-
Avi Spira, M.D., M.Sc.
Global Head, Interventional Oncology -
Philippe Szapary, M.D., M.S.C.E.
Clinical Development & Scientific Affairs Head, Interventional Oncology -
Hannah McEwen, Ph.D.
Head of Engineering, Interventional Oncology -
Stewart Bates, Ph.D.
Interim Head of Discovery and Translational Sciences for Interventional Oncology -
Stephen Pitt, Ph.D.
Global Head of External Innovation, Interventional Oncology -
Lisa Berry
Global Head of Strategy & Operations, Interventional Oncology
Featured stories & discussions
Could we be on our way to eliminating cancer for good?
What once seemed like an out-of-reach goal may soon be within our grasp. Learn how Johnson & Johnson is working toward its vision of helping create a world without cancer.
“No one would believe me when I suspected I had lung cancer”
Learn about one patient’s journey toward getting an accurate diagnosis—and why it’s crucial to always advocate for your health.
By the numbers: Helping to reduce disparities in cancer care
For World Health Day, learn how Johnson & Johnson’s commitment to Diversity, Equity and Inclusion is helping to deliver transformational cancer treatments and solutions that reach the patients who need them most.
